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Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) is known by its aggressiveness and lack of effective
therapeutic options. Thus, improvement in current knowledge of molecular changes associated with pancreatic
cancer is urgently needed to explore novel venues of diagnostics and treatment of this dismal disease. While there
is mounting evidence that long noncoding RNAs (lncRNAs) transcribed from intronic and intergenic regions of the
human genome may play different roles in the regulation of gene expression in normal and cancer cells, their
expression pattern and biological relevance in pancreatic cancer is currently unknown. In the present work we
investigated the relative abundance of a collection of lncRNAs in patients’ pancreatic tissue samples aiming at
identifying gene expression profiles correlated to pancreatic cancer and metastasis.
Methods: Custom 3,355-element spotted cDNA microarray interrogating protein-coding genes and putative
lncRNA were used to obtain expression profiles from 38 clinical samples of tumor and non-tumor pancreatic
tissues. Bioinformatics analyses were performed to characterize structure and conservation of lncRNAs expressed in
pancreatic tissues, as well as to identify expression signatures correlated to tissue histology. Strand-specific reverse
transcription followed by PCR and qRT-PCR were employed to determine strandedness of lncRNAs and to validate
microarray results, respectively.
Results: We show that subsets of intronic/intergenic lncRNAs are expressed across tumor and non-tumor
pancreatic tissue samples. Enrichment of promoter-associated chromatin marks and over-representation of
conserved DNA elements and stable secondary structure predictions suggest that these transcripts are generated
from independent transcriptional units and that at least a fraction is under evolutionary selection, and thus
potentially functional.
Statistically significant expression signatures comprising protein-coding mRNAs and lncRNAs that correlate to PDAC
or to pancreatic cancer metastasis were identified. Interestingly, loci harboring intronic lncRNAs differentially
expressed in PDAC metastases were enriched in genes associated to the MAPK pathway. Orientation-specific RT-
PCR documented that intronic transcripts are expressed in sense, antisense or both orientations relative to protein-
coding mRNAs. Differential expression of a subset of intronic lncRNAs (PPP3CB, MAP3K14 and DAPK1 loci)i n
metastatic samples was confirmed by Real-Time PCR.
Conclusion: Our findings reveal sets of intronic lncRNAs expressed in pancreatic tissues whose abundance is
correlated to PDAC or metastasis, thus pointing to the potential relevance of this class of transcripts in biological
processes related to malignant transformation and metastasis in pancreatic cancer.
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Pancreatic ductal adenocarcinoma (PDAC) is the most
common pancreatic neoplasm and accounts for > 85%
of pancreatic tumor cases [1]. PDAC is a devastating
disease with very poor prognosis for which the only
curative treatment is resection surgery [2]. However,
only 15-20% of patients have resectable pancreatic
tumor, and from these only 20% presents a 5-year survi-
val, which results in an average 5-year survival rate of 3-
5% [1]. PDAC aggressiveness is mainly associated to the
lack of early diagnosis tools and the limited response to
available treatments [2].
Large-scale gene expression studies of tumor samples
have been extensively employed to delineate the mole-
cular pathways and cellular processes involved in tumor-
igenesis and progression of PDAC [3] and to search for
novel biomarkers for diagnosis and molecular targets for
therapeutic intervention in pancreatic cancer [4]. In
spite of the wealth of information generated in recent
years on the most frequent molecular alterations found
in PDAC [5], there are still important open question in
pancreatic cancer biology such as the profound resis-
tance of primary and metastatic PDAC to chemo- and
radiotherapy [6]. Regarding the identification of molecu-
lar markers for pancreatic cancer diagnostic/prognostic,
while some promising candidate genes have been pro-
posed [4], none have been proven effective to signifi-
cantly improve early detection and to reduce mortality/
morbidity of the disease. Thus, a better understanding
of the molecular basis of pancreatic cancer is required
for the identification of more effective diagnostic mar-
kers and therapeutic targets.
Over the last decade, advances in genome-wide ana-
lyses of the eukaryotic transcriptome have revealed
that the majority of the human genome is transcribed,
producing large numbers of long (> 200 nt) noncoding
RNAs (lncRNAs) mapping to intronic and intergenic
regions [7-10]. These include subsets of polyadenylated
and non-adenylated transcripts that accumulate differ-
ently in the nucleus and cytoplasm of cells [10,11].
While only a small fraction of lncRNAs have been
characterized in detail, it is clear that these transcripts
may act through diverse molecular mechanisms and
play regulatory and structural roles in important biolo-
gical processes, such as in genomic imprinting, chro-
mosome inactivation, cell differentiation and
development, cell proliferation, protein nuclear import,
organization of nuclear domains and apoptosis (see
[12] for a review).
Altered expression of lncRNAs has been documented
in different types of human cancer [13-15] prompting
an increasing interest in their use as biomarkers for
diagnosis and prognosis as well as potential therapeutic
targets [14,16-19]. Increased expression of the lncRNA
MALAT-1 has been observed in several types of tumors,
including metastatic non-small cell lung cancer [19].
Recently, augmented levels of HOTAIR in primary
breast tumors were shown to correlate with breast can-
cer invasiveness and metastasis [18]. Measurement of
lncRNA PCA3 in patient urine samples has been shown
to allow more sensitive and specific diagnosis of prostate
cancer than the widely used marker prostate-specific
antigen (PSA) [16]. The lncRNA HULC is highly
expressed in hepatocarcinoma patients and detected in
the blood by conventional PCR methods [20].
There are several reports of aberrant expression of
microRNAs in PDAC [21,22], and there is potential in
their use as biomarkers for disease diagnosis [23,24].
However, there is a paucity of information regarding the
expression of lncRNAs in pancreatic cancer. In an inter-
esting study performed by Ting et al. it was observed
the aberrant overexpression of satellite repeat RNAs
(HSATII) ranging from 100 to 5000 nt in patients with
PDAC [25]. Interestingly, detection of HSATII by RNA
in situ hybridization was able to correctly diagnose
PDAC in tumor biopsies, including cases in which the
histopathology was non-diagnostic [25].
Our group has previously shown that most (at least
74%) annotated protein-coding gene loci generate intra-
genic lncRNAs that map to intronic regions [26]. Possi-
ble relevance of intronic lncRNAs to neoplastic
processes was proposed following the observation that
subsets of these transcripts are present in gene expres-
sion signatures correlated to the degree of malignancy
in prostate cancer [17] or to tissue histology in head
and neck tumors [27] and renal cell carcinoma [28]. In
addition, a number of intronic lncRNAs were found to
be regulated by androgen stimulation of cultured pros-
tate cancer cells [29], indicating that these transcripts
are expressed in a regulated manner and thus, corrobor-
ating the idea that intronic lncRNAs are biologically
relevant.
In this study, we used a custom cDNA microarray
platform with probes for lncRNAs expressed from intro-
nic and intergenic regions of the human genome, as
well as for a selected set of cancer-related protein-cod-
ing genes to generate expression profiles from a collec-
tion of tumor and non-tumor pancreatic tissue samples.
Expression of intronic/intergenic lncRNAs subsets was
detected across all samples tested. Enrichment of pro-
moter-associated chromatin marks indicate that these
transcripts originate from independent transcriptional
units. Over-representation of conserved DNA elements
and stable secondary structure predictions suggest that
at least a fraction of these transcripts are under evolu-
tionary selection and thus potentially functional.
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prising long noncoding RNAs that are significantly cor-
related with primary and metastatic ductal pancreatic
adenocarcinoma. This suggests that lncRNAs are modu-
lated during tumorigenesis and tumor progression and
therefore may participate in molecular processes rele-
vant to malignant transformation and metastasis in pan-
creatic cancer.
Results
Long noncoding RNAs from intronic and intergenic
regions are expressed in neoplastic and non-tumor
pancreatic tissues
In this work, a custom spotted cDNA microarray with
approximately 4,000 elements was used to investigate
the expression patterns of a collection of protein-cod-
ing transcripts and putative noncoding RNAs in clini-
cal samples of primary and metastatic tumor, chronic
pancreatitis and histologically normal pancreatic tissue.
This array platform has been described previously
[17,28] and contains probes that interrogate 2,371
RefSeq mRNAs from genes associated with cancer in
the literature, as well as 984 transcripts mapping to
intronic or intergenic regions of the genome and to
known lncRNAs. Fluorescent cRNA targets generated
from 38 pancreatic tissue samples (15 primary adeno-
carcinoma, 9 histologically normal adjacent tissue, 6
metastatic samples and 8 chronic pancreatitis) were
individually hybridized to microarrays in replicate.
After data filtering (see Methods for details), 1,607
transcripts were detected as expressed in at least one
histological type, being 1,267 protein-coding mRNAs
and 340 putative noncoding RNAs, including tran-
scripts with no overlap to RefSeq exons, i.e, mapping
to intronic and intergenic regions. Only candidate
lncRNAs sequences that showed genomic alignments
with at least 90% identity and coverage were further
analyzed, resulting in 335 transcripts (22 known
lncRNAs, 240 putative lncRNAs mapped to intronic
regions and 73 to intergenic regions).
Expression of comparable fractions of protein-coding
mRNAs and putative long noncoding transcripts map-
ping to intronic and intergenic regions was detected in
all histological tissue types (Table 1). The fraction of
intronic lncRNAs detected as expressed in the microar-
ray (240/722 = 0.33) is comparable to that of known
RefSeq lncRNAs (22/74 = 0.30) and intergenic lncRNAs
(73/188 = 0.39), and lower than the fraction of
expressed protein-coding mRNAs (1267/2371 = 0.53).
The smaller fraction of lncRNAs detected in pancreatic
tissues (0.30-0.39) compared to protein-coding mRNAs
(0.53) reflects the observation from other studies that
noncoding RNAs are generally less abundant and more
tissue-specific than protein coding mRNAs [9,26]. In
fact, we observed that the lncRNAs detected in pancrea-
tic tissue samples by array hybridization were on average
less abundant than protein-coding transcripts (average
intensities 24.9 and 31.6, respectively).
Of the 240 gene loci harboring intronic lncRNAs that
were detected in pancreatic tissues, only 62 had array
probes interrogating exons of mRNAs from the same
loci. From these, 31 (50%) were detected only in intronic
regions, pointing to a subset of lncRNAs that conceiva-
bly are generated by independent intronic transcription
rather than pre-mRNA splicing. Thirty one loci were
detected by both exonic and intronic probes (50%). For
each of these loci, Pearson correlation between the
expression of the lncRNA and mRNA across all pan-
creatic tissue samples was calculated. Correlations were
generally low (-0.5 < r < 0.5 for 27 out 31 loci), with 11
loci displaying a negative correlation between expression
of the intronic lncRNA and the mRNA, and 20 showing
a positive correlation.
To obtain further information regarding the correla-
tion between the 240 intronic lncRNAs expressed in
pancreatic tissues and the adjacent exons from the same
loci we analyzed their expression in a set of nine RNA-
seq libraries [30]. For each locus in each library, the
number of tags was normalized by RPKM (Reads Per
Kilobase of exon model per Million mapped reads).
Table 1 Gene expression detected in the microarrays according to probe type and pancreatic tissue histology
Detected as expressed in
Type # probes in the array NT
(n = 9)
T
(n = 15)
M
(n = 6)
CP
(n = 8)
# expressed probes *
protein-coding mRNA 2371 1106 1167 1198 1230 1267
Known lncRNA (RefSeq) 74 20 19 22 18 22
Intronic lncRNA 722 206 202 238 235 240
Intergenic lncRNA 188 68 68 74 77 78
Total 3355 1400 1456 1532 1560 1607
*To be considered as expressed, a probe signal should be detected above the median array intensity value in at least 75% of samples from at least one
histological type.
NT, non-tumor pancreatic tissue; T, primary pancreatic adenocarcinoma; M, metastases from primary pancreatic tumors; CP; chronic pancreatitis.
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the adjacent upstream/downstream exons were calcu-
lated if all elements (intronic lncRNA, upstream and
downstream exons) were detected in at least 4 out 9
RNAseq libraries. Seventy five loci (75/240, 31%) satis-
fied these criteria and were further analyzed. As
expected, we found a high correlation between the
expression of exons flanking intronic lncRNAs (66/75
with r > 0.5). We found that about a third of exon/
intron pairs showed positive correlation of expression
(24/75, r > 0.5). The expression of more than half of
exon/intron pairs were poorly correlated (46/75, -0.5 < r
< 0.5), and a small fraction was negatively correlated (5/
75, r < -0.5). The overall low correlation observed
between the expression of intronic lncRNAs and adja-
cent exons suggest that for the most part intronic
lncRNAs are processed and accumulate in the cell at
rates distinct from mRNAs produced in the same loci,
arguing against them being simply remainings of spli-
cing lariats.
To gain further insight into the expression pattern of
the 335 putative lncRNAs, we investigated their expres-
sion in other tissue types using publicly available RNA-
seq datasets generated from nine different tissue
histologies [30]. By cross-referencing the genome map-
ping coordinates of the pancreatic-expressed lncRNAs
with coordinates of the RNAseq reads we found that
approximately 80% of the former (267/335) are detected
in at least one other human tissue (Figure 1).
Coding potential of the 335 sequences mapping to
intronic and intergenic regions was investigated using
the Coding Potential Calculator (CPC) software [31].
This analysis showed that most sequences (322/335,
96%) have little or no protein coding potential. Thus, we
s u g g e s tt h a tm o s to ft h ei n t r o n i ca n di n t e r g e n i ct r a n -
scripts detected in pancreatic tissues are indeed noncod-
ing RNAs.
To document the length of the intronic transcripts
expressed in pancreatic samples we compared the set of
intronic RNA sequences (n = 240) with sequences
resulting from the assembly of ESTs and mRNAs depos-
ited in GenBank that map to intronic regions of the
genome, previously generated in our group and which is
available as a UCSC Genome Browser custom annota-
tion track [26]. We found that 190 out 240 intronic
transcripts (79%) are represented by an assembled
sequence contig. The mean length of the intronic con-
tigs is 779 bp, whereas the individual ESTs have a mean
length of 428 bp, suggesting that the ESTs spotted on
the microarray are partial sequences of longer noncod-
ing RNA transcripts.
We also investigated the proximity of 73 intergenic
lncRNAs to UTRs of annotated genes to evaluate if
these transcripts could represent untranslated regions of
incomplete mRNAs. We found that 14 intergenic tran-
scripts (14/73, i.e. 19%) map within 1 kb from a known
3’or 5’ UTR and could potentially extend the 3’ or 5’
untranslated region of a known protein-coding mRNA.
The remaining 59 transcripts map at least 1 kb away
from a known mRNA and possibly constitute yet unan-
notated intergenic noncoding RNAs.
To investigate if the intronic and intergenic RNAs
detected in pancreatic tissue could be precursors of
small regulatory ncRNAs, we compared the set of 335
lncRNAs expressed in pancreas to microRNA and
Figure 1 Intronic and intergenic lncRNAs detected in
pancreatic tissues comprise both tissue-specific and broadly
expressed transcripts. Genomic coordinates of 335 intronic/
intergenic transcripts detected as expressed in pancreatic tissues
were cross-referenced with genomic coordinates of transcripts
detected in RNAseq libraries from nine different tissues [30].
LncRNAs were grouped and colored by the number of tissue
libraries where their expression was detected (Y axis). RNAseq
libraries are ordered in the × axis according to the number of
pancreatic lncRNAs detected in each library.
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larity to known small RNA was found, except for one
sequence that mapped to the SNOR89 locus.C o n s i d e r -
ing that the average length of micro RNA precursors (>
1,000 nt) is greater than the average EST length (468 nt)
we extended the genomic coordinates of probe
sequences by 1 kb at both ends and repeated the
sequence comparison with known small RNA datasets.
Using this approach, we found four putative extended
EST sequences that show high similarity to seven addi-
tional small RNAs: hsa-mir-1259, hsa-mir-326, hsa-mir-
4269, hsa-mir-675, SNORD12, SNORD12B and
SNORD12C.
Sequence conservation among species is generally
viewed as an indication of functional significance of a
given genomic feature. We searched for evidence of
sequence conservation within the set of intronic/inter-
genic lncRNAs expressed in pancreatic tissues by com-
paring their mapping coordinates with those from
conserved DNA elements in vertebrates (phastCons
46way vertebrates), mammals (phastCons 46way placen-
tal) and primates (phastCons 46way primates) obtained
from the UCSC genome browser. After normalization
by the number of conserved elements present in each
group, relatively greater overlap with conserved DNA
elements was observed within primate, mammalian and
vertebrate sequences, in this order (Additional File 1,
Figure S1). The overlap of intronic/intergenic RNAs
with evolutionarily conserved DNA elements was greater
than the expected by chance alone, as judge by the over-
lap attained with a set of randomly selected intronic/
intergenic DNA sequences with same length and CG%
content (Fisher’se x a c tt e s tp < 0.05, Additional File 1,
Figure S1). In addition, a fraction of the lncRNAs map-
ping to intronic/intergenic regions (49 sequences out
335 analyzed, 15%) appear to fold into stable RNA sec-
ondary structures (P > 0.5) (http://verjo102.iq.usp.br/
sites/tahira/structures.html), as predicted by the RNAz
program [34]. Altogether, these observations provide
additional support to the notion that at least a fraction
of the noncoding transcripts mapping to intronic/inter-
genic regions may exert functional roles in pancreatic
cells.
Enrichment of promoter-associated chromatin marks
(H3K4me3) and start sites of capped transcripts suggest
that intronic lncRNAs are independent transcriptional
units
Given the paucity of information about the biogenesis of
lncRNAs originated from intronic and intergenic
regions, we searched for regulatory elements in the gen-
ome that could be associated to their transcriptional
control. First, we investigated the distribution of tri-
methylation of lysine 4 in histone 3 (H3K4me3), a
chromatin modification associated with regions of tran-
scription initiation [35], in the vicinity of intronic/inter-
genic lncRNAs. Genomic coordinates of H3K4me3
marks measured in 13 cell lineages [35] were obtained
from the UCSC Genome Browser. Only H3K4me3
marks with a p <1 0
-5 were used to limit the experimen-
tal noise. The nearest H3K4me4 mark relative to the
known boundaries of intronic/intergenic lncRNAs
(based on sequenced ESTs) expressed in pancreatic tis-
sues was selected and the distance annotated. As a con-
trol, the same analysis was performed using 100 random
sets of intronic or intergenic DNA sequences with same
length and GC content.
An enrichment of H3K4me3 marks was observed clo-
ser to the known boundaries for the set of intronic tran-
scripts expressed in pancreatic tissue samples (Figure 2,
p a n e lA ,b l u eb a r s ) .T h ed i stance distribution of
H3K4me3 marks relative to known boundaries of intro-
nic transcripts was significantly different (KS test, high-
est p < 0.05) from that observed for a random set of
sequences (same length and %CG), indicating that it is
not explained by chance alone. The same analysis was
performed with the set of expressed intergenic regions.
Although we observed a higher frequency of H3K4me3
marks closer to the known boundaries of the intergenic
transcripts, we found no statistically significant differ-
ence in their distribution relative to the random control
set (Figure 2, panel B, green bars).
As expected, we observed a higher frequency of
H3K4me3 marks closer to the known boundaries of pro-
tein-coding mRNAs (Figure 2, panel A, red bars). This
distribution is statistically different from the one
obtained with a control comprising a random sequence
set (KS test, highest p < 0.01). No statistically significant
difference was observed between pancreas-expressed
intronic/intergenic lncRNAs and mRNAs regarding the
distributions of promoter-associated H3K4me3 marks,
indicating that these distributions are similar. The
enrichment of promoter-associated H3K4me3 at the
vicinity of intronic/intergenic pancreatic-expressed tran-
scripts argues that these transcripts are independent
transcriptional units.
We also investigated the distribution of annotated
CpG islands relative to EST probes representing pro-
tein-coding mRNAs and noncoding intronic/intergenic
RNAs expressed in pancreatic tissues. To pursue this
analysis we used the genomic coordinates of CpG
islands available as a UCSC genome browser track. First,
we cross-referenced the coordinates of annotated CpG
islands with those of EST probes representing mRNAs
expressed in pancreatic tissues, which showed an enrich-
ment towards EST boundary coordinates (Figure 2,
panel C, red bars), significantly different from the distri-
bution observed by a random sequence set (KS test, p <
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islands was observed for intronic or intergenic sequence
sets relative to random sets with same length and CG%
content (KS test, p-value > 0.05) (Figure 2, panels C and
D, blue and green bars).
We also compared the known start sites of intronic/
intergenic lncRNAs with CAGE tags generated from
poly(A+) RNA from 6 different cell lineages (RIKEN).
We note that this set does not include CAGE libraries
derived from pancreatic tissues. As pre-processing, coor-
dinates of overlapped tags were clustered and only
clusters containing at least 5 tags were considered for
further analysis. Next, we calculated the distance of the
closest CAGE tag cluster to intronic/intergenic
lncRNAs, protein-coding mRNAs, and to random geno-
mic sequences. A significant enrichment (KS test, p <
0.05) of CAGE tags within 1kb of the known start of
intronic lncRNAs expressed in pancreatic tissues was
observed (Figure 2, panel E, blue bars). Although a
higher frequency of CAGE tags closer to the known
start site of intergenic lncRNAs was observed, the
enrichment was not statistically significant when
Figure 2 Genomic loci encoding intronic lncRNAs are enriched in promoter-associated histone marks and start sites of capped
transcripts. Distance distribution (X axis) of promoter-associated chromatin marks H3K4me3 binding sites (panels A, B), CpG islands (panels C, D)
and CAGE Tags (panels E, F) relative to genomic coordinates of intronic (blue bars) and intergenic (green bars) transcripts expressed in
pancreatic tissues (Y axis) were calculated. For comparison, distribution distances were calculated for an equal number of protein-coding mRNAs
(red bars) and for randomly selected intronic or intergenic genomic sequences with the same length and % GC of pancreas expressed lncRNAs
(light gray bars).
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green and gray bars).
Identification of a gene expression signature correlated
to ductal pancreatic cancer comprising protein-coding
and lncRNAs
To gain further insights on the putative biological rele-
vance of intronic/intergenic noncoding RNAs in pan-
creatic cancer we investigated their relative expression
in tumor and non-tumor pancreatic tissues. Identifica-
tion of genes specifically deregulated in malignant pan-
creatic epithelial cells is frequently confounded by an
augmented stromal component in the latter due to the
presence of proliferating stromal cells and infiltrating
inflammatory cells [36,37]. A similar desmoplastic reac-
tion is observed in chronic pancreatitis [38,39]. To favor
the identification of genes specifically altered in neoplas-
tic pancreatic cells, we performed a two-class analysis
comparing the expression profiles of 15 primary adeno-
carcinoma samples with nine histologically normal tissue
fragments adjacent to tumors combined to eight sam-
ples of chronic pancreatitis. Using this approach, we
found 147 transcripts differentially expressed in pancrea-
tic tumor samples relative to non-tumor tissues (FDR ≤
10%). This expression signature comprised 104 protein-
coding mRNAs and 43 lncRNAs, being 34 intronic and
9 intergenic transcripts (See Additional file 2, Table S1
for a complete list). As shown in Figure 3, except by
one sample (210, primary tumor), the 147-gene signa-
ture efficiently discriminated tumor and non-tumor tis-
sues. Conceivably, the prevalence of an inflammatory
component in the 210 sample could explain this sample
showing an expression profile more similar to chronic
pancreatitis samples.
Next, we performed a meta-analysis to compare the list
of protein-coding mRNAs presented in the pancreatic
Figure 3 A gene expression signature of pancreatic adenocarcinoma. A two-class statistical analysis (see Methods) identified 147 transcripts
(rows) differentially expressed (FDR ≤10%) between primary adenocarcinoma samples and histologically normal and chronic pancreatitis samples
combined (columns). Patient ID numbers are shown below the columns. Forty three transcripts mapping to intronic or intergenic regions were
identified (43/147, i.e. 29%). Expression level of each gene is represented by the number of standard deviations above (red) or below (blue) the
average value for that gene across all samples. Samples are ordered according to their individual correlation to the average profile of the
primary tumor samples. Sample tissue histology is shown below each patient ID.
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other gene expression studies with clinical samples of
pancreatic cancer, retrieved from the Pancreatic
Expression Database [40] (see Additional file 3, Table
S2). Twenty four out 104 protein-coding transcripts
detected in our analysis (24/104, i.e. 23%) were
reported in at least one of the 12 studies, comprising
15 different analyses, deposited in the Pancreatic
Expression Database. From these, expression changes
of 17 genes were confirmed by other studies, whereas
3 showed partial agreements and 4 showed an inverted
pattern of expression. Confirmed genes included genes
already reported in the literature and proposed as bio-
markers of pancreatic cancer such as S100A6, TIMP1,
NF-B, VCL and S100P [5,41-47]. It is worth mention-
ing that overexpression of S100P was detected in 11
different studies (Additional file 3, Table S2). We also
detected upregulation of MBOAT in pancreatic tumors.
Increased expression of MBOAT in ductal pancreatic
adenocarcinoma has been already reported and was
shown to inversely correlate to patient survival in pan-
creatic cancer [39].
A gene enrichment analysis using the DAVID analysis
suite [48] using as input either the list of protein-coding
mRNAs or of intronic transcripts differentially expressed
in pancreatic tumors was performed to investigate the
over-representation of specific molecular functions, bio-
logical processes and cellular components of the Gene
Ontology annotation [49]. For this analysis, intronic
transcripts were annotated according to the gene locus
where they map on the genome. Only categories having
corrected EASE score < 0.05 [48] were considered as
overrepresented.
Among the set of 104 protein-coding mRNAs differ-
entially expressed in pancreatic tumors we found an
enrichment of gene categories encoding proteins
involved in “focal adhesion” (p <0 . 0 3 ;TRIP6, TRIM25,
VCL, SDC1, ARPC2, DLC1, CDH1, ITGB5), “RNA trans-
port and localization “ (p < 0.01; THOC7, THOC2, RAN,
NUP85, THOC3) and localizing to “basolateral plasma
membrane” (p < 0.05; NOTCH4, ARPC1B, CDH1,
TRIP6, VCL, TRIM25, SDC1, DLC1). Deregulation in
pancreatic cancer of genes encoding proteins involved in
focal adhesion has already been reported in the litera-
ture [39]. Noteworthy, the gene category “RNA trans-
port and localization” comprises genes associated to the
TREX-complex (THOC2, THOC3). Increased expression
of this complex (Thoc1) in breast cancer correlates with
tumor size and the metastatic state of the tumor pro-
gression [50], thus suggesting that modulation of the
TREX-complex could also have a role in pancreatic can-
cer. No enriched gene category was found amongst gene
loci that harbor differentially expressed intronic
lncRNAs.
Ingenuity Pathway Analysis (IPA) [51] was used to
identify pathways and gene networks represented
amongst the sets of protein-coding mRNAs identified in
the pancreatic tumor gene expression signature. The
most enriched network, “cellular movement, cell-to-cell
signaling interactions and endocrine system” (p <1 0
-43)
comprised 23 differentially expressed transcripts and
included most genes represented in the enriched gene
categories identified using DAVID (see Additional file 4,
Figure S2). Gene networks associated with “cellular
movement, skeletal and muscular system development
and function and inflammatory response” (17 genes, p <
10
-29)a n d“carbohydrate metabolism, small molecule
biochemistry and infectious disease” (16 genes, p <1 0
-
28) were also identified.
Identification of genes correlated to metastasis in
pancreatic cancer
A hallmark of pancreatic cancer is the high prevalence
of metastatic disease, whose molecular basis is poorly
understood. To search for protein-coding and long non-
coding RNAs with expression levels correlated to the
metastatic phenotype in pancreatic cancer, we compared
expression profiles from 15 primary adenocarcinoma
samples with those obtained from 6 distant metastases
originated from primary pancreatic adenocarcinoma.
Metastatic samples were collected from secondary
tumors appearing in different target sites (1 from perito-
neum, 1 from ganglion, 4 from liver), from different
patients. Using a significance threshold of FDR ≤ 5%, we
identified a metastasis-associated signature comprising
355 differentially expressed transcripts (Figure 4). From
these, 221 are protein-coding mRNAs and 134 are non-
coding RNAs (134/355, 38% of signature), from which
101 map to intronic, 27 to intergenic genomic regions
and 6 are known lncRNAs (a complete list is available
as Additional file 5, table S3).
Gene enrichment analysis using protein-coding
mRNAs differentially expressed in metastatic samples
identified the over-representation of genes involved in
“nucleic acid transport” and “RNA localization “ (p <
0.03; THOC7, THOC2, RAN, NUP85, THOC3, NUP88).
A similar analysis performed with gene loci harboring
intronic lncRNAs differentially expressed in metastasis
showed enrichment of gene categories pertaining to
“MAPK signaling pathway” (p <0 . 0 3 ;ARRB1, ATF2,
MAPK1, MAP2K5, MAP3K1, MAP3K14, PPP3CB,
RAPGF2 and TGFbR2), “phosphate metabolic process”
(p < 0.05; ABL2, ENPP2, PTEN, CSNK1D, TYK2,
MAPK1, MAP2K5, MAP3K1, MAP3K14, PPP3CB,
PPP2R2A, PASK, TNK2, DAPK1 and TGFbR2), “non-
membrane-bounded organelle” (p < 0.02; ABL2, GPHN,
ITPR1, SORBS1, TYK2, MAPK1, MAP2K5, MAP3K1,
NDRG1, DST, MCPH1, USH1C, MAEA, BBS5, SLC4A7,
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NOP58, ATF3, ALMS1, STON2, DAPK1 and MYO5A)
and “actin filament-based process"(p < 0.05; ABL2,
SORBS1, PACSIN2, CNN3, MYO5A and DST).
Ingenuity Pathway Analysis identified significantly
enriched gene networks amongst protein-coding genes
differentially expressed in metastasis. The most enriched
gene network of differentially expressed protein-coding
mRNAs (p <1 0
-41) included genes related to “cellular
movement, gene expression and immune cell trafficking”
(see Additional file 6, Figure S3). Among these we found
that up regulation of S100A4, NCAM1 and LIMK1 had
already been associated with metastatic behavior in pan-
creatic cancer [52-54]. While the remaining genes in the
network had not been associated with metastasis in pan-
creatic cancer yet, most of them have previously shown
to be involved with malignancy or metastatic behavior
in other types of cancer (see Additional file 7, Table S4
for a complete list). Other gene networks enriched in
protein-coding mRNAs deregulated in metastatic tumor
samples were “cell cycle, genetic disorder, metabolic dis-
ease” (21 genes, p <1 0
-33), “cardiovascular system devel-
opment and functions, embryonic development and
tissue development” (21 genes, p <1 0
-30)a n d“cancer,
Figure 4 A gene expression signature correlated to metastasis in pancreatic adenocarcinoma. Three hundred fifty five transcripts (rows)
identified as differentially expressed (FDR ≤ 5%) between metastatic (dark box) and primary tumor (dark gray) samples from 21 patients
(columns). Patient ID numbers are shown below the columns. One hundred thirty four intronic and intergenic lncRNAs were identified,
comprising 38% of the metastasis signature. Expression level of each transcript is represented by the number of standard deviations above (red)
or below (blue) the average value across all samples. Samples are ordered according to their individual correlation to the average profile of
primary tumor samples. Tissue histology is shown below each patient ID.
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10
-29). IPA analysis also highlighted the prevalence of
genes related to cell death within the metastasis-signa-
ture. It comprised 42 protein-coding mRNAs related to
apoptosis (19 down-regulated and 23 up-regulated), in
line with the notion that perturbation of the normal
programmed cell death is involved in the metastatic
phenotype in pancreatic cancer [6,55]. Interestingly, we
found 6 intronic lncRNAs mapped to locus of apoptosis-
related genes among those present in the metastasis sig-
nature (ATF2, TGFbR2, MAP2K5, MAP3K1, DAPK1
and PTEN).
Metastasis-associated intronic lncRNAs are expressed with
antisense and/or sense orientation relative to
corresponding protein-coding genes
To document in more detail the structure of lnc RNAs
mapping intronic regions of gene loci related to the
MAPK pathway or to apoptosis, which were over-repre-
sented in the metastasis-signature, we investigated their
orientation relative to the corresponding protein-coding
mRNA. Orientation-specific RT-PCR was employed to
determine the strandedness of the eleven intronic tran-
scripts mapping to introns of MAPK pathway or/and
apoptosis-related genes, namely ARRB1, ATF2, MAPK1,
MAP2K5, MAP3K1, MAP3K14, PPP3CB, RAPGF2,
TGFbR2, DAPK1 and PTEN. These experiments were
performed using total RNA isolated from pancreatic
tumor tissue samples or from cultured MIA PaCa-2
cells. Ten transcripts showed evidence of being
transcribed with the same (sense) orientation of the cor-
responding protein-coding mRNA in both pancreatic
tissue samples and MIA PaCa-2 cells (Figure 5). Inter-
estingly, a transcript with antisense orientation relative
to the protein-coding mRNA was detected in an intro-
nic region of PPP3CB in MIA PaCa-2 cells. When RNA
from pancreatic tumors was used, antisense intronic
transcription was detected in three additional loci
(ATF2, TGFBR2 and MAP3K1), which produced both
sense and antisense messages (Figure 5).
The relative abundance of the eleven intronic
lncRNAs identified in genes from the MAPK pathway or
related to apoptosis was evaluated by quantitative Real-
Time PCR in RNA samples isolated from primary
tumors and distant metastasis. We initially measured
the abundance of each of the 11 intronic transcripts in
three samples of primary adenocarcinoma and three
samples of metastasis. In spite of a great variability due
to small sample size, 7 out 11 intronic transcripts
showed a similar expression change (same direction) as
measured in the microarray. Since the amount of RNA
from clinical samples were limiting, we selected for
further validation in additional samples three intronic
lncRNAs, being one antisense (PPP3CB)a n dt w ow i t h
the same orientation (MAP3K14 and DAPK1) relative to
the protein-coding gene. As shown in Figure 6, statisti-
cally significant increased expression of all three intronic
lncRNAs was observed.
We next asked if the expression changes of these
intronic transcripts would reflect in the expression of
Figure 5 LncRNAs deregulated in pancreatic cancer metastasis map to intronic regions of genes associated with the MAPK pathway
and/or related to apoptosis. Transcriptional orientation of eleven intronic lncRNAs mapping to MAPK pathway and/or apoptosis-related gene
loci (ARRB1, ATF2, MAPK1, MAP2K5, MAP3K1, MAP3K14, PPP3CB, RAPGF2, TGFbR2, DAPK1 and PTEN) was investigated by strand-oriented
reverse transcription followed by PCR. For each gene, sense (S) or antisense (AS) transcription was measured. Controls (C) for the absence of self-
annealing during reverse transcription (RT) were obtained by performing RT reactions in the absence of primers (RT+, Primer -). Controls for the
absence of genomic DNA contamination were obtained by omitting reverse transcriptase in the RT reaction (RT-, Primer +).
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RT-PCR experiments with primers interrogating pro-
tein-coding mRNAs from PPP3CB, MAP3K14 and
DAPK1 loci showed no statistically significant expression
change between primary tumors and metastasis samples.
To investigate the co-expression of protein-coding
mRNAs and intronic lncRNAs from the same loci we
measured the Pearson correlation of their expression
Figure 6 Expression changes of intronic lncRNAs mapping to PPP3CB, MAP3K14 and DAPK1 loci are not accompanied by changes in
the corresponding protein-coding mRNAs. Relative levels of intronic lncRNAs and protein-coding mRNAs from PPP3CB (A), MAP3K14 (B) and
DAPK1 (C) loci were determined by Real-Time PCR in clinical samples of primary adenocarcinoma (circles) or distant metastasis (squares) from
pancreatic cancer patients. For each transcript, the number of tested samples is indicated in the × axis. For each gene, results are expressed as
fold-change relative to the average expression of primary tumor samples. For each sample, qPCR assays were performed in triplicate and mean
values are shown. House-keeping gene HMBS was used as the endogenous control for normalization across patient samples. All intronic
transcripts (left panels) were differentially expressed in metastatic samples at a significance threshold of p< 0.05 (PPP3CB, p = 0.0259; MAP3K14,
p = 0.0069; DAPK1, p = 0.0035). Protein-coding transcripts (right panels) were not significantly differentially expressed.
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relation (r = 0.78, p < 0.013) was observed for the
MAP3K14 locus, suggesting that the intronic sense tran-
script may be a by-product of pre-mRNA processing of
the protein-coding transcript (see discussion for details).
No significant correlation between protein-coding
mRNAs and intronic lncRNAs was observed for the
other two loci (p > 0.05), leaving open the possibility
that intronic RNAs mapping to PPP3CB (antisense) and
DAPK1 (sense) loci are noncoding RNAs originated
from independent transcriptional events.
Discussion
In this work we investigated gene expression profiles
from clinical samples of pancreatic cancer using a cus-
tom cDNA microarray enriched in probes that interro-
gate long potentially noncoding RNAs mapping to
intronic and intergenic regions of the human genome,
plus a collection of protein-coding genes previously
associated with cancer in the literature. By comparing
expression profiles of 38 pancreatic clinical samples with
four distinct tissue histologies (primary adenocarcinoma,
adjacent non-tumor tissue, chronic pancreatitis, metasta-
sis), we detected in all types of pancreatic tissues studied
a proportion of intronic and intergenic transcripts com-
parable to the one observed for protein-coding mRNAs.
There are several reports of aberrant expression of
microRNAs [21-24], but this is to our knowledge the
first time that the expression of lncRNAs has been stu-
died in pancreatic cancer.
W eo b s e r v e dt h a tm o s ti n t r o n i ca n di n t e r g e n i ct r a n -
scripts expressed in pancreatic tissues have little or no
coding potential (96% of total). Comparison with
sequence contigs resulting from the assembly of EST/
mRNA data produced in our group [26] showed that
these transcripts have a mean size of at least 779 nt,
being longer than the EST probes deposited in the
microarrays, which represent indeed only parts of longer
noncoding RNAs transcribed from intronic regions.
Most putative intergenic transcripts (~81%) were located
more than 1 kb apart from an UTR of an annotated
gene, suggesting that for the most part, these are indeed
intergenic transcripts rather than uncharacterized
untranslated regions of incomplete mRNAs.
While it is clear that lncRNAs may exert diverse cellu-
lar functions through multiple molecular mechanisms
[12,56,57], it has been suggested that a fraction of the
transcriptome noncoding complement may correspond
to transcriptional noise resulting from RNA polymerase
activity in regions of open chromatin or intronic seg-
ments of processed mRNAs [58]. Our expression mea-
surements of intronic lncRNAs do not permit to
distinguish between i) intron lariats resulting from spli-
cing of a pre-mRNA or ii) independent transcriptional
units located within intron-annotated genomic regions.
We have focused on poly(A+)-selected RNA fractions
followed by oligo-dT primed reverse transcription to
minimize the chance of labeling targets from non-polya-
denylated spliced lariats. We argue that the identifica-
tion of subsets of transcripts that map to intronic
regions and whose steady-state levels allows the detec-
tion by microarrays indicate that these are not rapidly
turned-over intron lariats. We have also performed a
series of analysis to obtain additional evidence to sup-
port the notion that intronic/intergenic lncRNAs
detected in pancreatic tissues are indeed bona fide cellu-
lar transcripts, as discussed below.
We first sought independent confirmation of intronic/
intergenic lncRNA expression using RNAseq data gener-
ated from 9 distinct tissue libraries [30]. We found that
approximately 80% of intronic/intergenic lncRNAs
detected in pancreatic tissues were also detected in at
least one RNAseq library (Figure 1). Most transcripts
confirmed by the RNAseq data were detected i) only in
a single tissue type other than pancreas, or ii) in all 9
tissue libraries plus pancreas, indicating the prevalence
of subsets of noncoding transcripts with broad or speci-
fic tissue-type expression patterns, respectively (Figure
1).
While only a fraction of the intronic/intergenic
lncRNAs expressed in pancreatic tissues overlapped evo-
lutionarily conserved DNA elements in vertebrates,
mammals and primates, we observed a significant
enrichment (p < 0.05) compared to randomly selected
control regions. This result suggests that at least a frac-
tion of these lncRNAs are under purifying selection in
the vertebrate lineage and therefore must be biologically
functional. For the remaining transcripts, absence of
sequence conservation should not be taken as evidence
of no biological relevance, since it is known that well-
characterized functional lncRNAs are poorly conserved
across their global sequence [59].
As proposed by Washielt et al. [60], mapping con-
served RNA secondary structure may lead to the discov-
ery of novel functional lncRNAs. We found that a small
fraction of lncRNAs expressed in pancreas (15%. i.e. 49/
335) are predicted to form stable structural domains
that could be important for their processing or biologi-
cal function. It is well documented in the literature that
small regulatory RNAs can be generated by processing
of long RNA precursors transcribed from intronic and
intergenic regions of the genome [56]. To ask what frac-
tion of our set of lncRNAs expressed in pancreatic tis-
sues could be precursor of small RNAs we compared
their sequences to those of known microRNA and
snoRNA [32,33]. Only a discrete overlap was found,
indicating that long intronic/intergenic transcripts are
predominantly not precursors of known microRNAs/
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transcripts may represent precursors of uncharacterized
novel small RNAs.
We found significant enrichment of H3K4me3, a pro-
moter-associated chromatin mark frequently found in
RNA Pol II transcribed regions [35,61], in the vicinity
(up to 2 kb) of intronic (p < 0.05) noncoding transcripts
as compared to randomly selected genomic DNA
sequences. A comparable H3K4me3 enrichment was
observed nearby known protein-coding transcripts, sug-
gesting that transcription of protein-coding mRNAs and
intronic lncRNAs initiates at promoter regions with
similar chromatin contexts. We also observed a signifi-
cant enrichment of CAGE tags proximal to known start
sites of intronic lncRNAs expressed in pancreatic tis-
sues, corroborating the notion that at least a fraction of
these is independent transcriptional units. Since pan-
creatic tissues were absent from the study that gener-
ated the CAGE tags used for cross-reference, these
results possibly underestimate the co-localization of
intronic/intergenic lncRNAs with bona fide transcription
start sites of capped transcripts.
Differently from protein-coding mRNAs, we did not
find significant enrichment of CpG island in the vicinity
of intronic and intergenic RNA sequences expressed in
pancreatic tissues. Based on this observation, we pro-
pose that methylation of CpG islands is not involved in
the transcriptional regulation of most intronic/intergenic
lncRNAs expressed in pancreatic tissues. Nonetheless,
the full set of observations regarding the structure, con-
servation and genomic context argues that at least a
fraction of intronic/intergenic transcripts detected in
pancreatic tissues are independent transcriptional units
rather than transcriptional noise originated from ran-
dom Pol II firing [62], prompting us to investigate in
more detail their relative expression levels in tumor and
non-tumor pancreatic tissues.
Differential expression of intronic lncRNAs in prostate
and renal cancer has already been documented [17,28].
Here we extend these observations to pancreatic cancer,
asking whether there were sets of intronic/intergenic
lncRNAs deregulated in clinical samples of pancreatic
tumor. Comparing expression profiles from primary
tumors with samples from histologically non-malignant
pancreatic tissue and chronic pancreatitis (CP) we iden-
tified a 147-gene signature correlated with primary pan-
creatic tumor. This strategy was devised to favor the
identification of tumor specific markers rather than
transcripts associated with the stromal cell component,
which is augmented in both tumor and CP samples
[36,37]. We sought to validate the pancreatic cancer
expression signature by performing a meta-analysis with
published gene expression studies of pancreatic cancer.
Only 23% of the protein-coding mRNAs present in our
pancreatic cancer signature were also identified in other
reports. This modest overlap can be accounted for by
differences in platforms and the heterogeneity of pan-
creatic tumor samples. Notwithstanding, we observed a
high agreement (17/24, 71%) between the expression
changes measured in our signature and those retrieved
from published data, which provides independent sup-
port for our result and validates our sample set and
methodological approach. This set included genes
already reported in the literature as differentially
expressed in pancreatic cancer and that have been inves-
tigated as biomarkers for pancreatic cancer (i.e. S100A6
[47], S100P [46], TIMP1 [63] and NF-B [64]). In agree-
ment with previous findings [5], the analysis of gene
enriched categories in the pancreatic cancer expression
signature indicated the over-representation of genes
involved in focal adhesion. Over-representation of focal
adhesion genes in the pancreatic cancer signature is sug-
gestive that deregulation of genes encoding proteins
involved in the connection and signaling to the extracel-
lular matrix plays an important role in the malignant
transformation and/or maintenance of pancreatic adeno-
carcinomas. This set included integrin beta 5 (ITGB5),
which we found to be upregulated in pancreatic adeno-
carcinoma. Itgb5 protein has been investigated as diag-
nostic biomarker in non-small cell lung cancer [65] and
is target of the inhibitor drug EMD121974, which is
under clinical trial [66]. Thus, ITGB5 is an attractive
candidate to be tested as biomarker and/or new drug
target in pancreatic cancer.
Interestingly, a significant fraction (29%) of the 147-
gene signature correlated with primary pancreatic tumor
was comprised by lncRNAs mapping to intronic or
intergenic regions, suggesting that noncoding RNAs
could exert roles related to tumorigenesis of pancreatic
cancer. This result prompted us to investigate the exis-
tence of subsets of lncRNAs with expression levels
altered in metastatic samples.
We identified a statistically significant metastasis sig-
nature of 355 differentially expressed transcripts that
includes 220 protein-coding genes, 134 intronic/inter-
genic transcripts and 6 known lncRNAs (Figure 4 and
Additional file 5, Table S3). In addition to protein-cod-
ing genes previously shown to be deregulated in pan-
creatic metastasis (7 out of 19), the metastasis signature
comprises known genes already associated to metastasis
in other types of cancer (Additional file 7, Table S4),
thus pointing to potentially interesting candidates for
testing as new targets for treatment of the metastatic
disease in pancreatic cancer.
The significant fraction of lncRNAs in the metastasis
signature (38% of total) suggests that deregulation of
these lncRNAs could also be associated with the meta-
static process. Expression changes of protein-coding
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been described in pancreatic carcinoma [67-69]. Here
we found 9 intronic lncRNAs mapped to genes corre-
lated to the MAPK pathway in the metastasis signature.
We also identified expression changes in gene loci
related to apoptosis, including 42 protein-coding
mRNAs and 6 intronic lncRNAs; this pathway was one
out of 12 described by Jones et al. [6] as genetically
altered in pancreatic cancer. Four intronic lncRNAs
belong to both categories. These results prompted us to
document in more detail the nature of the 11 transcripts
mapping to intronic regions of gene loci associated with
the MAPK pathway or related to apoptosis, i.e., their
relative orientation to the corresponding protein-coding
mRNAs.
Strand-specific RT-PCR assays using RNA aliquots
from tumor tissue samples showed that 4 intronic tran-
scripts have antisense orientation relative to the protein-
coding mRNA: PPP3CB, ATF2, TGFBR2 and MAPK1.
Antisense transcripts originated in PPP3CB intronic
regions were also detected in MIA PaCa-2 cells. The
antisense orientation relative to the corresponding pro-
tein-coding mRNA provide strong evidence to support
that these noncoding RNAs are produced from indepen-
dent transcriptional units, possibly under control of a
different promoter region.
Transcripts mapping to intronic regions with the same
orientation of the corresponding protein-coding mRNA
were detected in the ATF2, TGFBR2 and MAPK1,a s
well as in the 7 other gene loci tested (ARRB1,
MAP3K1, MAP3K14, MAP2K5, PTEN, DAPK1 and
RAPGF2), in both tissue and MIA PaCa-2 RNA samples.
These sense-oriented intronic transcripts could indeed
be bona fide RNAs originated from independent tran-
s c r i p t i o n ,b u ta l s or e s u l tf r o mr e v e r s et r a n s c r i p t i o no f
unprocessed mRNA precursors or of stable RNA lariats
generate during pre-mRNA splicing. Further experi-
ments will be necessary to determine the precise nature
of these sense-oriented intronic RNAs.
The relative abundance of two sense (DAPK1,
MAP3K14) and one antisense-oriented (PPP3CB) intro-
nic transcripts in samples of primary pancreatic adeno-
carcinoma and pancreatic metastases was independently
accessed by qRT-PCR, confirming the results measured
in the microarray hybridizations. Four additional intro-
nic lncRNAs showed concordant results between qRT-
PCR and the microarrays (ARRB, RAPGF2, ATF2 and
PTEN). Expression changes of 4 intronic lncRNAs were
not concordant between qRT-PCR and microarray
(MAP3K1, TGFBR2, MAP2K5 and MAPK1). The
amount of RNA and the number of patient tissue sam-
ples available for the qRT-PCR experiments were limit-
ing, and the marginally significant and non-validated
lncRNA candidates were tested only in few samples in
an initial round of validation. It is possible that some of
the intronic lncRNA candidates that failed the initial
round of validation would still be validated as differen-
tially expressed if tested in additional tissue samples.
However, an alternative explanation for the non-valida-
tion of some candidates is the presence of array hybridi-
zation artifacts such as cross-hybridization or target
amplification biases.
Intragenic lncRNAs have been shown to modulate in
cis the expression of mRNAs expressed in the same
locus [29,70,71]. We measured the relative abundance of
mRNAs produced in the PPP3CB, DAPK1 and
MAP3K14 loci in the same samples and did not observe
statistically significant expression differences between
primary tumors and metastasis. This result indicates
that intronic RNAs produced in these loci do not affect
in cis the abundance of the corresponding protein-cod-
ing transcripts. This conclusion is also supported by the
absence of significant correlation between expression
levels of protein-coding and noncoding RNAs originat-
ing from PPP3CB and DAPK1 loci. The possibility that
intronic lncRNAs differentially expressed in metastatic
samples may exert regulatory functions acting in trans
is compelling and warrants further studies.
It has been shown that a significant portion of the
noncoding component of the human transcriptome is
comprised of non-polyadenylated RNAs [10]. We note
that our analysis was limited to the set of lncRNAs
interrogated by the array platform (Table 1) and by the
use of poly(A+)-enriched RNA, and therefore is not
comprehensive in terms of describing the full comple-
ment of lncRNAs expressed in pancreatic tissues. Thus,
additional studies using unbiased approaches such as
RNAseq or tiling arrays will be required to catalog all
poly(A+) and poly(A-) transcripts expressed in pancrea-
tic tissues with distinct degrees of malignancy and for
the identification of novel regulatory lncRNA candidates
involved in the malignant transformation and tumor
progression.
Conclusions
In this work we report that noncoding RNAs originating
from intronic and intergenic genomic regions are
expressed in tumor and non-tumor pancreatic tissues.
Enrichment of promoter-associated chromatin marks
plus the observation of antisense orientation of intronic
transcripts relative to mRNAs expressed from the same
loci provide evidence that these messages are not by-
products of random transcription or pre-mRNA splicing
but rather, are independent transcriptional units.
Further investigation will be required to determine the
biogenesis of these lncRNAs.
We identified gene expression signatures correlated to
primary and metastatic stages of pancreatic cancer,
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collections of long intronic and intergenic noncoding
RNAs. Further studies will be necessary to reveal possi-
ble biological functions and molecular mechanisms
exerted by these lncRNAs in tumorigenesis and/or pro-
gression of pancreatic tumors.
In summary, our work contributes with novel candi-
date biomarkers of pancreatic cancer and highlights the
importance of investigating the biological relevance of
long noncoding RNAs in order to fully understand the
molecular basis of the disease.
Methods
Patient Samples and Cell Lines
A total of 38 pancreatic samples stored in freshly-frozen
tissue collections were obtained with informed consent
from patients seen at Hospital das Clínicas, Faculdade
de Medicina da Universidade de São Paulo (HC-
FMUSP). Primary tumor tissues (T) were obtained from
15 patients with no evidence of metastasis. Nine samples
of histologically normal pancreatic tissue fragments
(NT) were dissected from non-neoplasic tissue sections
adjacent to tumor sites. Six samples of metastases origi-
nated from primary pancreatic tumors (M) were
obtained from biopsies in affected organs (one from
peritoneum, one from ganglion and four from liver tis-
sues). Eight tissue samples from patients with chronic
pancreatitis (CP) were also collected. All tissue sections
were reviewed by a pathologist for histological confirma-
tion and whenever necessary, macro-dissected to guar-
antee that 80% or more of the sections used for gene
expression analysis were composed of neoplastic/pan-
creatitis tissue.
Pancreatic carcinoma cell lines MIA PaCa-2 were
obtained from the American Type Culture Collection
and maintained using DEMEM supplemented with 10%
(v/v) fetal calf serum (FCS), 3 mM L-glutamine, 100 μg/
ml streptomycin and 100 U/ml penicillin.
RNA extraction and microarray target preparation
Total RNA was extracted from pancreatic tissue samples
(50-100 mg tissue) using Trizol (Invitrogen) according
to manufacturer’s recommendations. RNA cleanup
including a DNase I digestion step was performed using
RNeasy spin columns (Qiagen). RNA integrity was mea-
sured by the relative abundance of 28S/18S ribosomal
subunits, verified through micro fluid capillary electro-
phoresis (Agilent Bioanalyzer 2100).
To generate cRNA targets, 1 μgo ft o t a lR N Af r o m
each sample was linearly amplified in two rounds of
reverse transcription followed by in vitro transcription
according to Wang et al. [72]. Briefly, oligo dT-T7 was
used to prime first-strand cDNA synthesis (SuperScript
III First Strand Synthesis - Invitrogen). After second-
strand cDNA synthesis (cDNA Polymerase Mix - Clon-
tech), cRNA targets were produced by in vitro transcrip-
tion (MegaScript T7 - Ambion). In the second round of
amplification, cRNAs produced in the first-round were
reverse transcribed using random hexamer primers and
used as template for in vitro transcription in the pre-
sence of amino-allyl UTP. Prior to hybridization, cRNA
targets were labeled by coupling with mono-reactive
Cy5-esters (Amersham). Quantification of cDNA yield
and dye incorporation was performed using a NanoDrop
spectrophotometer (Thermo Scientific). Typically, 50-
100 μg of cRNA were obtained following two rounds of
linear amplification. Two sets of cRNA targets were gen-
erated from each RNA sample and independently hybri-
dized to microarray slides.
Microarray design and hybridization
Construction of the spotted custom-cDNA microarray
platform was described previously [17]. Probes were
selected from the over 1 million EST clone collection
generated during the Human Cancer Genome Project, a
large-scale EST sequencing project that used cDNA
libraries generated from poly(A) mRNA derived from
over 20 different types of human tumors [73,74]. Tran-
scripts from the EST dataset were annotated as protein-
coding, putative intronic lncRNA or intergenic lncRNA
following mapping to the human genome sequence and
cross-referencing with genome mapping coordinates of
annotated genes (RefSeq dataset) [17]. Intronic/inter-
genic lncRNAs used for microarray spotting were ran-
domly selected from the annotated EST dataset.
Transcripts annotated as “intronic lncRNAs” comprise
sequences that mapped within an intronic region of a
protein-coding gene. Transcripts annotated as “inter-
genic lncRNAs” comprise sequences that map to geno-
mic regions devoid of any annotated gene. To be
annotated as intronic or intergenic a given transcript
could not overlap a genomic region spanning an exon of
annotated protein-coding genes. “Known lncRNAs” refer
to transcripts whose genomic coordinates overlap fully
with the coordinates of noncoding RNAs from the
RefSeq dataset (accession Id = NR_nnnnnn). Transcripts
annotated as “protein-coding gene” overlapped with
exons of protein-coding RefSeq transcripts in genomic
space. To account for possible unannotated intron
retention events, partial transcripts mapping to exon/
intron boundaries were annotated as “exonic”.
In the course of this work microarray probes were re-
mapped to the latest version of the human genome
(hg19) and re-annotated to reflect updated RefSeq and
UCSC gene models (Oct. 2010). Each glass-slide con-
tains 3,355 cDNA fragments spotted in duplicate, plus
positive (cDNA from housekeeping genes) and negative
(plant and bacterial DNA) controls. Spotted cDNAs
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annotated (RefSeq) protein-coding genes, 74 ESTs map-
ping to known RefSeq lncRNAs, 188 ESTs mapping to
intergenic regions of the genome. The array also con-
tained 2,371 ESTs mapping to exons of protein-coding
genes associated with cancer based on a literature search
[17], comprising genes involved in apoptosis, tumorigen-
esis, metastasis, cancer metabolism and cancer
progression.
For each sample, cRNA targets were ressuspended in a
final volume of 200 μl of 1× Microarray Hybridization
Solution v.2.0 (GE Healthcare) containing 25% forma-
mide, denaturated at 92°C for 2 minutes and incubated
with microarrays at 42°C for 16 hours using an auto-
mated slide processor (GE Healthcare). Following
sequential washes in 1× SSC; 0.2% SDS, 0.1× SSC; 0.2%
SDS and 0.1× SSC; 0.2% SDS, microarray slides were
scanned immediately in a Generation III Microarray
Systems Scanner (Molecular Dynamics/GE Healthcare).
For each sample, two slides were hybridized with differ-
ent preparations of cRNA targets. As probes are spotted
in duplicate in the arrays, a total of 4 replicate measure-
ments were collected for each cDNA for each sample.
Data processing and analysis
Cy5-intensity measurements from hybridized targets
were extracted from array images using the ArrayVision
software (Imaging Research Inc.). To make the expres-
sion values comparable across all samples tested, the
raw data was normalized by the quantile method [75].
Next, for each slide, the fifty percent of probes with the
lowest intensity values were filtered out. A mean expres-
sion value for each probe, in each patient sample, was
calculated when at least 3 out of 4 replicates showed
valid measurements. Only probes with valid measure-
ments in at least 75% of the samples in any of the histo-
logical groups (NT, T, PA or M) were selected, resulting
in a total of 1,607 probes for further analysis. The Com-
Bat program was used to remove systematic variations
in gene expression across experiments resulting from
the use of different batches of microarrays [76]. Inter-
slide Pearson correlations using normalized intensities
from all probes in the array were calculated before and
after filtering and normalization of data intensities. Raw
data intensities showed average inter-slide correlations
of 0.63, whereas normalized data showed inter-slide cor-
relation of 0.83.
Raw and normalized microarray intensities were
deposited in the Gene Expression Omnibus database
(GEO - http://www.ncbi.nlm.nih.gov/geo/) under acces-
sion number GSE30134.
Significance analysis of microarrays (SAM) approach
[77] was employed to identify gene expression signatures
correlated to tissue histology, with the following
parameters: two or multi-class response, 1000 permuta-
tions, K-Nearest Neighbors Imputer, and false discovery
rate (FDR) ≤ 10% or ≤5%. For representation of gene
expression measurements in heat-maps, samples were
ordered according to their individual correlation to the
average profile of the primary tumor samples.
Bioinformatics analyses
We used the BEDTools software package [78] to cross-
reference genome mapping coordinates (GRCh37 build,
hg19) of our dataset of intronic/intergenic noncoding
sequences with those from the various datasets used in
this analysis and available through the UCSC Genome
Browser [66]: i) RNAseq data of PolyA
+ RNA-derived
libraries from 9 tissues [30], ii) RIKEN CAGE tag data
from PolyA
+ RNA-derived libraries from 6 cell lineages
[79]; iii) ChIP-seq data of H3K4m3 DNA binding sites
[35], iv) conserved DNA elements in vertebrates, mam-
malian and primates calculated with PhastCons program
[66], v) predicted CpG islands [80] and vi) intronic non-
coding RNAs assembled from EST/mRNA GenBank
data [26].
To test the statistical significance of the overlap
between our dataset of intronic/intergenic lncRNAs and
the datasets of conserved elements and regulatory motifs
(H3K4me3, CpG islands, CAGE tags), we generated 100
groups of randomly selected sequences from intronic or
intergenic regions of the human genome matching in
number, length and CG content our set of expressed
noncoding sequences. As pre-processing of CAGE tag
data, coordinates of overlapped tags were clustered and
only clusters containing at least 5 tags were considered
for further analysis. Fischer’s exact test was used to test
the statistical significance (p <0 . 0 5t h r e s h o l d )o ft h e
enrichment of conserved DNA elements in intronic/
intergenic lncRNAs relative to the enrichment observed
for the 100 random sequence sets.
For the analysis of transcription regulatory elements,
we first computed the distance of the closest H3K4me3
marks, predicted CpG islands and CAGE tags to our set
of expressed intronic/intergenic lncRNAs, expressed
protein-coding mRNAs, and of the set of 100 random
groups. Transcription regulatory elements mapping to
5’UTRs of known transcripts (RefSeq and UCSC genes)
were removed to avoid the contribution of signals at
start sites of known genes to the enrichment of regula-
tory elements at start sites of intronic lncRNAs mapping
nearby.
Only regulatory elements distant up to 10 kb of
sequence boundaries were considered. Next, non-para-
metric Kolmogorov-Smirnov (KS) test statistics, imple-
mented using the Deducer package under R language
[81] was used to compare the distance distributions of
H3K4me3 marks, predicted CpG islands and CAGE tags
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and those calculated for each of the 100 control random
sets. Distance distributions of regulatory motifs from
intronic/intergenic lncRNAs/protein-coding mRNAs
were considered significantly different from the obtained
by chance if all KS p-values calculated using each ran-
dom set were smaller than 0.05.
Protein-coding potential of intronic and intergenic
lncRNAs was evaluated using the Coding Potential Cal-
culator software [31] with default parameters. RNAz
program [34] was used to predict structurally conserved
and thermodynamically stable RNA secondary struc-
tures. Only predicted structures with P > 0.5 were con-
sidered as containing conserved secondary structures.
Orientation-specific RT-PCR
Aliquots of DNAse-treated total RNA from a pool of six
pancreatic tumor tissues samples or from Mia PaCa-2
cells were used as template in orientation-specific
reverse transcription reactions. Reactions were per-
formed with 200 ng total RNA plus 2.5 μMo fo l i g o n u -
cleotide primers designed to detect sense or antisense
strand intronic transcripts, relative to the orientation of
the mRNA from the same locus. SuperScript III™ Super
Mix (Invitrogen) was used according manufacture’s
recommendations, with the following modification:
reverse transcription reaction was increased to 57°C to
limit RNA self-annealing. To verify the absence of prim-
ing due to self-annealing or genomic DNA contamina-
tion, control reactions were performed without addition
of primers or of reverse transcriptase, respectively.
Real-time RT-PCR
One microgram aliquots of DNase-treated total RNA from
11 clinical samples of primary pancreatic tumors (5
already used in the microarray experiments and 6 new
samples) and 6 of distant metastases with pancreatic origin
(4 already used in the microarray and 2 new samples) were
reverse transcribed using SuperScript III™ Super Mix kit
(Invitrogen) and random hexamer primers according to
manufacturer’s recommendation. Relative abundance of
selected transcripts primary tumor/metastasis samples was
determined by real-time PCR using the ABI PRISM
® 7300
Real Time PCR System and the SYBR Green PCR Master
Mix kit (Applied Biosystems). Reactions were performed
in a final volume of 20 μlc o n t a i n i n ga5μla l i q u o to f
diluted cDNA (1:7) and 1 μM of forward and reverse
gene-specific primers. Expression levels of hydroxymethyl-
bilane synthase (HMBS) [82] appeared to be constant and
was used as a reference gene to make expression measure-
ments comparable across all different samples tested. For
quantitative results, the level of each transcript was nor-
malized by the level of HBMS, and represented as fold
change using the 2
-ΔΔCt method [83], where ΔΔCt = (Ct
candidate gene in sample × - Ct reference gene in sample
X)sample -m e a nΔCt of all primary tumor samples tested.
Additional material
Additional File 1: Figure S1: Intronic/intergenic lncRNA are enriched
in conserved DNA elements. Genomic coordinates of conserved DNA
elements identified in Vertebrate, Placental or Primate sequences (see
Methods for details) were cross-referenced to those from lncRNAs
expressed in pancreatic tissue (blue bars). These presented a higher
overlap with evolutionary conserved DNA elements than the observed
for a random set of genomic DNA sequences with same length and CG
content (gray bars) (Fisher’s test p< 0.05). Bar heights indicate the
number of lncRNAs that overlap conserved DNA elements in each
taxonomic group divided by the total number of conserved DNA
elements present in each group.
Additional File 2: Table S1: List of transcripts differentially
expressed in PDAC relative to chronic pancreatitis and non tumor
tissue samples combined.
Additional File 3: Table S2: Validation of protein-coding genes
differentially expressed in PDAC by meta-analysis of published
data.
Additional File 4: Figure S2: Genes modulated in pancreatic cancer
are involved in cellular movement, cell-to-cell signaling interactions
and endocrine system. Ingenuity Pathway Analysis was used to identify
gene networks over-represented among the set of 104 protein-coding
genes differentially expressed in PDAC samples. The most significantly
enriched network (p =1 0
-43) is comprised by 23 differentially expressed
genes measured in the microarrays. Red indicates higher expression, and
green, lower expression in tumor tissues relative to chronic pancreatitis
and adjacent non-tumor tissue samples combined.
Additional File 5: Table S3: List of genes differentially expressed
between PDAC and metastatic tissue samples.
Additional File 6: Figure S3: Genes modulated in metastatic
pancreatic cancer are involved in cellular movement, gene
expression and immune cell trafficking. Ingenuity Pathway Analysis
was used to identify gene networks over-represented among the set of
221 protein-coding genes differentially expressed in PDAC relative to
metastasis tissue samples. The most significantly enriched network (p=
10
-41) is comprised by 24 differentially expressed genes measured in the
microarrays. Red indicates higher expression, and green, lower expression
in metastasis relative to PDAC tissue samples.
Additional File 7: Table S4: Genes from the pancreatic cancer
metastasis signature related to tumor aggressiveness in other
cancer types.
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